🇺🇸 GEFAPIXANT in United States

16 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cough — 3 reports (18.75%)
  2. Asthma — 2 reports (12.5%)
  3. Diarrhoea — 2 reports (12.5%)
  4. Drug Ineffective — 2 reports (12.5%)
  5. Taste Disorder — 2 reports (12.5%)
  6. Abdominal Discomfort — 1 report (6.25%)
  7. Abdominal Distension — 1 report (6.25%)
  8. Abdominal Pain — 1 report (6.25%)
  9. Acute Coronary Syndrome — 1 report (6.25%)
  10. Angioedema — 1 report (6.25%)

Source database →

GEFAPIXANT in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is GEFAPIXANT approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for GEFAPIXANT in United States?

Marketing authorisation holder not available in our data.